Lifang Pharmaceutical has received approval from China's National Medical Products Administration for its Azilsartan Medoxomil Potassium tablets, indicated for treating adult primary hypertension. This marks a significant step for the company in the pharmaceutical sector. The approval covers both 40mg and 80mg dosages of the medication. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON Company received drug registration certificate from regulatory body. [lever_c_demoted from research: ic=1 ai=0.1]